Duncan Bridgeman
|
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
KPG - Kiwi Property Green Bond offer closed
PFI - Capital Change Notice - FY27 LTI Scheme Grant
IKE - 1H FY27 Performance Update
SUM - Summerset Appoints Sue Matthews as Independent Director
GNE - FY27 Q1 Performance Report
FPH - F&P Healthcare statement regarding cyber incident
HGH - Heartland Group confirms leadership endorsements
October 22nd Morning Report
VCT - Operational Performance for the 3 months ended 30 Sept 2026
SKL - Skellerup with strong start, forecasts growth for FY27